Abstract: Embodiments of the present invention provide compounds (such as Formula (I) compounds, Formula (II) compounds, and various embodiments thereof). Compositions comprising those compounds are also provided. Methods for their preparation are included. Also, uses of the compounds are included, such as administering and treating diseases (e.g., cancer and infections).

Abstract: The present invention relates to a method of inhibiting cellular uptake of pro-nerve growth factor (proNGF) in a cell expressing neurotrophin p75 receptor in a mammal in need thereof. Such mammals include, for example, those suffering from neuropathological conditions. In another aspect, the invention relates to a method of promoting cellular uptake of proNGF in a cell expressing p75NTR receptor in a mammal in need thereof. Such mammals include, for example, those suffering from conditions relating to human and other mammalian hair follicle cycling.

Abstract: A water-free concentrate, consisting of ubiquinone Q10, a medium-chained triglyceride or triglyceride mixture, ?-lipoic acid and/or its derivative as well as one or more emulsifiers with HLB value between 9 and 19 permitted according to the foodstuff or drug laws has been described.

Abstract: Use of idebenone for the preparation of a medicament for the treating of a muscular dystrophy in particular for treating and/or preventing weakness and/or loss of skeletal muscle tissue and/or cardiomyopathy associated with a muscular dystrophy.

Abstract: The invention proposes the sure of reduced glutathione in a liposome (liposomal reduced glutathione) for the oral administration of a therapeutically effective amount to ameliorate the progression of vascular disease, including atherosclerosis, diabetes, hypertension, narrowing of arteries leading to decreased blood flow, ischemic events, and the formation of blood clots, abnormal platelet aggregation, and thrombotic events, by reducing the amount and effect of oxidized cholesterol, oxidized HDL and oxidized LDL. The invention also proposes combining liposomal encapsulated glutathione with statin drugs to improve the effect of lowering not only cholesterol but also the oxidized cholesterol as well as oxidized HDL and oxidized LDL. The invention also proposes combining liposomal encapsulated glutathione with CoQ10 as a therapy for vascular disease and management of side effects of statin therapy.

Abstract: The present invention relates to a composition comprising an NF?B-inhibitor and a non-retinoid collagen promoter.

Abstract: The present invention refers especially to 3,5-dihydroxy-2,4-cyclohexadienones of the general formula (I) wherein R1 and R2 are independently from each other C1-6-alkyl, C2-6-alkenyl or x-oxo-Cx-alkyl with x being an integer from 1 to 6, preferably R1 and R2 are independently from each other C2-6-alkenyl or y-oxo-Cy-alkyl with y being an integer from 2 to 5, and wherein R3 and R4 are independently from each other hydroxy, C1-6-alkyl, C2-6-alkenyl or x-oxo-Cx-alkyl with x being an integer from 1 to 6, preferably R3 and R4 are independently from each other hydroxy or y-oxo-Cy-alkyl with y being an integer from 2 to 5, for use as mood balancing agents and stress relievers, as well as to dietary compositions and fortified food/feed/beverages containing such 3,5-dihydroxy-2,4-cyclohexadienones of the general formula (I), and their uses.

Abstract: Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, stroke (MELAS), Kearns-Sayre Syndrome (KSS), are disclosed, as well as compounds useful in the methods of the invention, such as 2-(3-hydroxy-3-methyl-butyl)-6-(het)aryl-p-quinone or as 2-(3-hydroxy-3-methylbutyl)-3-(het)aryl-p-quinone derivatives. Energy biomarkers useful in assessing the metabolic state of a subject and the efficacy of treatment are also disclosed. Methods of modulating, normalizing, or enhancing energy biomarkers, as well as compounds useful for such methods, are also disclosed.

Abstract: Compositions and methods are provided for prophylactic or therapeutic treatment of a mammal for hearing or balance impairments involving neuronal damage, loss, or degeneration, by administration of a therapeutically effective amount of a redox-active therapeutic. Also provided are improved compositions and methods for treatments requiring administration of a pharmaceutical having an ototoxic side-effect in combination with a therapeutically effective amount of a redox-active therapeutic to treat the ototoxicity.

Abstract: The present invention relates generally to treatment of muscle pain and/or fatigue and to methods for treatment of side effects of statin therapy. In particular, the invention relates to the use of certain substituted benzoquinones, e.g. Coenzymes Q, particularly Coenzyme Q10 (Q10), in therapy. The invention also relates to the use of Q10 in combinative therapy with other agents such as uridine, its biological precursors or salts, esters, tautomers or analogues thereof (“uridine related compounds”). The invention is also directed to compositions, uses and combination packs or kits related to the treatment methods.

Abstract: In recent years the demand for cosmetic compositions and cosmetic methods for improving the appearance and condition of skin has grown enormously; consumers are seeking topical skin care products that help treat or delay the signs of natural (chronoaging) and environmental aging. The present invention relates to topical compositions for application to human skin and to their use in improving the condition and appearance of skin. It is based on the premise that effective treatment of normal skin conditions due to natural or environmental aging, such as wrinkles, lines, sagging, hyperpigmentation and age spots, and/or of sensitive, dry, rough, flaky, red, itchy, irritated skin may be obtained through the application of cosmetic compositions to the skin which comprise a combination of collagen stimulators, phytoestrogens, plant derived anti-inflammatory agents, fatty acid, antioxidants.

Abstract: A coenzyme Q10-containing water soluble composition comprises coenzyme Q10, a hydrophilic polyglycerol fatty acid ester, a lipophilic sucrose fatty acid ester and an aqueous phase component and a process for producing the same are disclosed. A coenzyme Q10-containing water-soluble dry powder can be obtained by drying the above-mentioned coenzyme Q10-containing water soluble composition. A food, functional food, beverage, pharmaceutical product, quasi drug, cosmetic, or animal food can be obtained by using the above-mentioned coenzyme Q10-containing water soluble composition or the above-mentioned coenzyme Q10-containing water-soluble dry powder. The coenzyme Q10-containing water soluble composition has a high bioavailability, and maintains a stable emulsion form for a long period of time from refrigeration temperature to room temperature and allows efficient supply.

Abstract: Methods of treating or preventing diseases associated with low bone mass in a mammal in need of such treatment or prevention comprising administering to the mammal a therapeutically effective amount of an agent that increases tryptophan hydroxylase 2 activity or of an agonist of the brain serotonin HT2C receptor. Diseases associated with low bone mass include osteoporosis, osteopenia, Paget's disease, osteomalacia, and renal osteodystrophy.

Abstract: An article, such as a container or bag for garbage, which repels animals such as cats, dogs, rats, and crows. The article may be made from a synthetic resin composition including a synthetic resin and from 10 to 15,000 ppm by weight of a salicylic acid ester, menthol and/or camphor. The article may also be made from a synthetic resin composition including a synthetic resin and an odorant composition containing eucalyptus oil and one or more of a salicylic acid ester, menthol and camphor.

Abstract: Systems and methods are provided herein that provide for promoting cellular health and treatment of cancer, and allied diseases such as diabetes and glaucoma.

Abstract: The presently claimed and disclosed inventive concept(s) contemplates a novel polymeric oral dosage form (transmucosal delivery vehicle) for delivery of pharmaceutical and nutriceutical bioactive agents to the mucosa and bloodstream of the intestine. The oral dosage form of the presently claimed and disclosed inventive concept(s) comprises a polymeric coating which encapsulates the bioactive agent and inhibits degradation and dissolution of the bioactive agent within the stomach and within the lumen of the intestine until after passing through the mucosal wall of the small and/or large intestine. The enzymatic degradation of the polymeric delivery vehicle containing the bioactive agent is substantially inhibited until after absorption of the polymeric delivery vehicle into blood vessels of the intestinal mucosa.

Abstract: The present invention is directed to pest-controlling compositions comprising as active ingredients one or more ?-diones, particularly ?-diketones and ?-triketones, and to the use of these compositions inter alia for preventing, eradicating, destroying, repelling or mitigating harmful, annoying or undesired pests including insects, arachnids, helminths, molluscs, protozoa and viruses. The present invention is further directed to processes of preparing ?-diones by de novo synthesis or from natural sources such as volatile oil-bearing plants from families including Alliaceae, Apiaceae, Asteraceae, Cannabinaceae, Lamiaceae, Pteridaceae, Myrtaceae, Myoporaceae, Proteaceae, Rutaceae and Zingiberaceae.

Abstract: Microbicidal compositions including (a) cyanodithiocarbimate and (b) an N-alkyl heterocyclic compound; a triazole compound or salt thereof or metal complex thereof; a microbicide with an activated halogen atom or a formaldehyde releasing compound; 1,4-bis(bromoacetoxy)-2-butene; 2-(thiocyanomethylthio)benzothiazole; a methylene-bis(thiocyanate); a halogenated acetophenone; a halopropynl compound; an iodosulfone; a phenol; a halocyanoacetamide compound and/or a quaternary ammonium compound are described. Components (a) and (b) can be present in a synergistically effective amount to control the growth of at least one microorganism. Methods for controlling the growth of microorganisms with the compositions are also disclosed.

Abstract: Provided are essentially preservative-free personal care product compositions that comprise a combination of fragrance compounds that stabilises the personal care product against microorganisms. The combination comprises certain benzaldehyde or benzaldehyde derivative compounds combined with certain fragrant acids. The composition is free of classical preservatives including parabens or their derivatives. Further provided are methods of forming such compositions and products and the use of the combination of fragrance compounds in such compositions and products.

Abstract: Trisubstituted phenol compounds and methods of using the compounds, e.g., for anesthetizing a subject, are disclosed.

Abstract: The present invention relates to new substituted hydroxyphenylamine based modulators of hormone and/or pigment levels, pharmaceutical compositions thereof, and methods of use thereof.

Abstract: The present invention relates generally to treatment of muscle pain and/or fatigue and to methods for treatment of side effects of statin therapy. In particular, the invention relates to the use of certain substituted benzoquinones, eg Coenzymes Q, particularly Coenzyme Q10 (Q10), in therapy. The invention also relates to the use of Q10 in combinative therapy with other agents such as uridine, its biological precursors or salts, esters, tautomers or analogues thereof (“uridine related compounds”). The invention is also directed to compositions, uses and combination packs or kits related to the treatment methods.

Abstract: The present invention relates to a fish feed comprising dioxabicyclo[3.3.0]octane derivates, in particular selected sesame lignans, and a vegetable oil or oil mixture comprising at least one 18-carbon chain omega-3 fatty acid. The dioxabicyclo[3.3.0]octane derivate will induce a desaturation and elongation of the 18-carbon chain fatty acid in the fish muscle into longer carbon chain polyunsaturated fatty acids.

Abstract: Compounds and methods for multi-targeted protein kinase modulation for angiogenesis, cancer treatment or the inflammatory pathways associated with those conditions are disclosed. The compounds and methods disclosed are based on substituted 1,3-cyclopentadione compounds.

Abstract: The present invention provides masking compositions that include a lower alkyl carboxylic acid, e.g. acetic acid. Also provided is a masking composition that includes (a) a lower alkyl carboxylic acid (e.g. acetic acid), a warming sensate (e.g. vanillin or vanillyl butyl ether) and/or a cooling sensate (e.g. menthol or isopulegol).

Abstract: It is intended to provide compositions and foods for use in the treatment, prophylaxis, or amelioration of diseases or symptoms which can be treated, prevented or ameliorated by activating PPAR, in particular, insulin resistant diabetes and hyperlipidemia. Namely, medicinal compositions usable in treating, preventing or improving diseases or symptoms which can be treated, prevented or ameliorated by activation PPAR which contain humulones, isohumulones or lupulones or pharmaceutically acceptable salts or solvates thereof.

Abstract: CoQ1O has a stimulatory effect on fibroblasts and keratinocytes, increases ATP production, decreases pain. The formulations are useful for promoting acute wound healing, fatigue and treatment of acute and chronic pain.

Abstract: Methods of treating or suppressing pervasive developmental disorders (PDDs) including; autistic disorder, Asperger's syndrome, childhood disintegrative disorder (CDD), Rett's disorder, and PDD-not otherwise specified (PDD-NOS) or attention deficit/hyperactivity disorder (ADHD) comprising administering to a subject in need thereof a therapeutically effective amount of one or more compounds as disclosed herein.

Abstract: The present invention relates to the use of xanthoxyline, and of plant extracts containing it, in cosmetic compositions.

Abstract: A pharmacologically effective mixture of a polymyxin composition and a hop composition having a synergistic effect on bacteria greater than the antibacterial effect of those compositions administered separately.

Abstract: The present invention relates to the field of food technology and delivery of hydrophobic biologically active compounds, particularly nutrients, via food products and beverages. In particular the present invention provides isolated casein micelles useful for the encapsulation of hydrophobic nutrients, therapeutic and cosmetic compounds, compositions thereof and methods of preparing the micelles.

Abstract: The invention relates to compositions and processes for reducing the level of blood glucose or ameliorating diabetic symptoms in a subject by treatment with the composition which includes one or more safe and suitable hops acids or hops acid derivatives. More specifically, the process comprises using an ingredient or applying to a food or a nonfood product a composition-comprising beta hops acids in order to reduce blood glucose levels in Type 2 diabetics or its related diseases.

Abstract: Palatable, solid oral formulations or compositions include at least one bioactive agent capable of chemical sterilization of human and animal males. Depending on the targeted species, the bioactive formulations comprise suitable additives, excipients, water-swellable compositions, and/or processing aids and can be made into uncoated or coated forms to modulate the release profile of the bioactive agents. Among the bioactive agents are zinc compounds and complexes and organic drugs with established pharmacological activities, which are traditionally unrelated to any form of contraception.

Abstract: The present invention relates to the compounds of the general formula (I), a composition for and a method of treating breast cancer or other proliferative disorders in a subject using a compound of general formula [I], wherein the substituents are as defined in the specification.

Abstract: The present invention refers especially to 3,5-dihydroxy-2,4-cyclohexadienones of the general formula (I) wherein R1 and R2 are independently from each other C1-6-alkyl, C2-6-alkenyl or x-oxo-Cx-alkyl with x being an integer from 1 to 6, preferably R1 and R2 are independently from each other C2-6-alkenyl or y-oxo-Cy-alkyl with y being an integer from 2 to 5, and wherein R3 and R4 are independently from each other hydroxy, C1-6-alkyl, C2-6-alkenyl or x-oxo-Cx- alkyl with x being an integer from 1 to 6, preferably R3 and R4 are independently from each other hydroxy or y-oxo-Cy-alkyl with y being an integer from 2 to 5, for use as mood balancing agents and stress relievers, as well as to dietary compositions and fortified food/feed/beverages containing such 3,5-dihydroxy-2,4-cyclohexadienones of the general formula (I), and their uses.

Abstract: The present invention pertains to the use of a compounds for the manufacture of a medicament for use in the treatment of a proliferative condition, wherein the compounds have the following formula: wherein: each of RB2, RB3, RB4, and RB5 is independently —H, —OH, or —OMe; each of R1 and R2 is independently: —H, optionally substituted C1-4alkyl, or optionally substituted C5-20aryl; RA3 is —H, —OH, —OC(?O)RE, —OS(?O)2OH, or —OP(?O)(OH)2; RE is: —H, optionally substituted C1-6alkyl, optionally substituted C3-20 heterocyclyl, or optionally substituted C5-20aryl; or a pharmaceutically acceptable salt, solvate, amide, ester, ether, chemically protected form, or prodrug thereof. The present invention also pertains to such compounds, pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, for both diagnosis and treatment of, for example, proliferative conditions, such as cancer, and inflammatory conditions.

Abstract: The present invention relates to substituted hydroxyacetophenone derivatives having antiproliferative and antimicrobial properties, to pharmaceutical compositions containing them, as well as to a method of preparing them. Moreover, the hydroxyacetophenone derivatives according to the invention can serve as organic intermediates for the preparation of biologically active compounds.

Abstract: A method of preventing or treating fatigue in a subject mammal comprises administering an effective amount of a composition comprising (a) reduced coenzyme Q represented by the following formula (1): wherein n is an integer of 1 to 12, and (b) lipoic acid or a derivative thereof, to the mammal.

Abstract: The present invention relates to a novel polymorphic form of atovaquone. More particularly, it relates to a novel crystalline form, that has improved solubility and other bulk characteristics suitable for pharmaceutical application. The present invention also relates to processes for preparing a new polymorphic form of atovaquone and its use in industry.

Abstract: Compositions comprising apocynin and paeonol. The compositions may be used for the treatment of inflammatory disease.

Abstract: The present invention provides an MMP-inhibitory composition comprising chalcone or its derivatives. They inhibit the MMPs in collagenase subfamily as well as those in gelatinase subfamily. The MMP inhibitory activity of chalcone derivatives was similar to or greater than that of parent compound, chalcone. Chalcone or its derivatives of the present invention inhibit activity of matrix metalloproteinase, so that it can be applied to treat and prevent diseases related to matrix metalloproteinase.

Abstract: Disclosed herein is a pharmacophore model for arthropod repellent activity and methods of making and using thereof. The pharmacophore comprises two hydrophobic aliphatic functions, one aromatic function and one hydrogen bond acceptor function. The pharmacophore model was made using a test set of arthropod repellent compounds. Also disclosed are arthropod repellent compounds identified by screening databases with the pharmacophore model. Also disclosed are methods of repelling arthropods from a surface or area. Compositions and formulations comprising the compounds of the present invention as well as objects having the compounds of the present invention are disclosed.

Abstract: A cosmetic composition has an association of at least three of the following substances with anti-free radical activity, selected from: A cosmetic composition has an association of at least three of the following substances with anti-free radical activity, selected from: 1) ebselen; or idebenone; or an association of the two; and 2) at least one substance with anti-free radical activity, or at least two substances with anti-free radical activity for obtaining said association of at least three substances with anti-free radical activity, said substance(s) being selected from: a) a substance of chemical formula (I) below: in which: R=a linear or branched, saturated or unsaturated C1-C16 hydrocarbon chain; and R1, R2 and R3 are identical or different and are a hydrogen atom or a methyl or methoxy radical, and its esters; b) an extract of Edelweiss; c) an extract of Emblica; and d) N-acetylcysteine. The anti-free radical activity is greatly improved.

Abstract: Pyrocatechin derivatives of formula I wherein R illustrates a group of formulae Ia, Ib, Ic or Id R1 is 4-halogen-but-2-enyl, R2 is lower alkyl or cycloalkyl, R3 is lower alkoxy and R4 is lower alkoxy lower alkoxy, or, where R is a group of formula (Ia), it is hydroxy, hydroxy lower alkoxy or a group of formula Ie R5 is reactive esterified hydroxy, R6 is azido and R7 is lower alkyl, lower alkenyl, cycloalkyl or aryl lower alkyl, and their salts, are valuable intermediates in the production of active ingredients for medicaments.

Abstract: The compound represented by the general formula (I) is administered to a subject suffering from diabetes or obesity. In the formula (I), R1 and R2 independently represent an aliphatic hydrocarbon group having 1 to 10 carbon atoms or phenyl group, and arbitrary hydrogen atoms on the aliphatic hydrocarbon group and the phenyl group may be replaced by halogen, X1 represents halogen, and X2 represents hydrogen or halogen.

Abstract: Methods and pharmaceutical preparations for treating heart failure by administering to a human or animal subject a therapeutically effective amount of at least one substance selected from the group consisting of a) SOD mimics (e.g., Tempol), b) NADPH oxidase inhibitors (e.g., Apocynin) and c) other substance that inhibit or reduce the amount of superoxide present in the affected tissues (e.g., the subjects heart and/or blood vessels) and/or increase levels of nitric oxide.

Abstract: Small molecules and their derivatives are described for the treatment and/or prevention of intestinal fluid loss. Also disclosed are methods of using said molecules and their derivatives to treat and/or prevent conditions associated with increased levels of 3?,5?-adenosine monophosphate. Specific compositions of the invention are also novel.

Abstract: The present invention relates to a modified polysaccharide prepared from the reaction between a polysaccharide comprising a plurality of monosaccharide subunits having at least one primary amino group, and an hydrophobic aldehyde. The aldehyde and the amino group form together an imine or amine group. The process for preparation and use in cosmetic, pharmaceutical and food industry of the modified polysaccharide is also disclosed.

Abstract: A method for the prophylaxis or treatment of inflammatory skin conditions, which method comprises applying to the skin a cosmetic or pharmaceutical preparation comprising licochalcone A and phenoxyethanol. This Abstract is not intended to define the invention disclosed in the specification, nor intended to limit the scope of the invention in any way.

Abstract: The invention relates to the use of idebenone for the preparation of a topically-applied composition which is intended to inhibit melanogenesis, to reduce cutaneous coloration or to brighten same and/or produce cutaneous depigmentation. More specifically, the invention relates to a topically-applied composition comprising a cosmetic, pharmaceutical and/or dermatologically-effective amount of idebenone, derivatives thereof or mixtures of same, in which there is an effective amount of idebenone or the derivative thereof such as to produce cutaneous depigmentation.